Copyright
©The Author(s) 2022.
World J Clin Cases. Dec 16, 2022; 10(35): 12909-12919
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12909
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12909
Follow-up lp (a) CV | ||||
Parameter | Overall, n = 2712 | < 0.22, n = 1388 | ≥ 0.22, n = 1324 | P value |
Demographics | ||||
Age, yr | 64.0 (58.0, 72.0) | 64.0 (58.0, 72.0) | 64.0 (57.0, 72.0) | 0.593 |
Male, n (%) | 1957 (72.2) | 982 (70.7) | 975 (73.6) | 0.102 |
BMI, kg/m2 | 24.7 (22.7, 26.1) | 24.6 (22.6, 26.1) | 24.7 (22.8, 26.2) | 0.191 |
Current smoking, n (%) | 710 (26.2) | 337 (24.3) | 373 (28.2) | 0.024a |
Diabetes, n (%) | 692 (25.5) | 327 (23.6) | 365 (27.6) | 0.019a |
Hypertension, n (%) | 1727 (63.7) | 869 (62.6) | 858 (64.8) | 0.251 |
Previous PCI, n (%) | 172 (6.3) | 92 (6.6) | 80 (6.0) | 0.584 |
Laboratory measurements | ||||
Average TC level, mmol/L | 3.67 (3.23, 4.18) | 3.67 (3.24, 4.16) | 3.67 (3.21, 4.19) | 0.737 |
Average LDL-C level, mmol/L | 1.80 (1.50, 2.18) | 1.80 (1.49, 2.17) | 1.79 (1.50, 2.18) | 0.968 |
Average HDL-C level, mmol/L | 1.00 (0.86, 1.18) | 1.03 (0.88, 1.20) | 0.98 (0.84, 1.15) | < 0.001a |
Average TG level, mmol/L | 1.34 (1.04, 1.83) | 1.32 (1.02, 1.75) | 1.37 (1.06, 1.91) | 0.002a |
Average CRP level, mg/L | 1.52 (0.80, 2.83) | 1.40 (0.72, 2.60) | 1.65 (0.87, 3.00) | < 0.001a |
Average WBC level, × 109/L | 6.38 (5.51, 7.25) | 6.30 (5.46, 7.25) | 6.43 (5.55, 7.26) | 0.089 |
Average lp (a) level, mg/dL | 14.00 (7.32, 34.90) | 16.70 (7.16, 45.81) | 12.52 (7.36, 25.48) | < 0.001a |
Lp (a) SD | 3.38 (1.61, 7.49) | 2.19 (0.95, 5.40) | 4.55 (2.61, 9.16) | < 0.001a |
Lp (a) CV | 0.22 (0.14, 0.32) | 0.14 (0.10, 0.18) | 0.32 (0.26, 0.43) | < 0.001a |
Lp (a) VIM | 0.17 (0.13, 0.23) | 0.13 (0.10, 0.15) | 0.24 (0.20, 0.29) | < 0.001a |
Medication, n (%) | ||||
Statin | 2675 (98.6) | 1379 (99.4) | 1296 (97.9) | 0.002a |
Ezetimibe | 451 (16.6) | 218 (15.7) | 233 (17.6) | 0.204 |
ACEI or ARB | 1588 (58.6) | 776 (55.9) | 812 (61.3) | 0.005a |
Beta blocker | 1639 (60.4) | 823 (59.3) | 816 (61.6) | 0.228 |
- Citation: Zhang SS, Hu WY, Li YJ, Yu J, Sang S, Alsalman ZM, Xie DQ. Lipoprotein (a) variability is associated with mean follow-up C-reactive protein in patients with coronary artery disease following percutaneous coronary intervention. World J Clin Cases 2022; 10(35): 12909-12919
- URL: https://www.wjgnet.com/2307-8960/full/v10/i35/12909.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i35.12909